Skip to main content
. 2020 Jul 17;2(4):5–11. doi: 10.1016/j.sopen.2020.07.002

Table 3.

Operative variables analyzed

LA + M + K group
(n = 38)
LA + F group
(n = 60)
P value
Surgical diagnosis, n (%)
Colorectal cancer 16 (42.1) 33 (55)
Gastric cancer 9 (23.7) 7 (11.7)
Non-neoplastic bowel obstruction 4 (10.5) 8 (13.3) .265
Gallbladder disease 5 (13.2) 3 (5)
Other 4 (10.5) 9 (15)
Urgency, n (%) 13 (34.2) 33 (55) .072
Surgical procedure, n (%)
Colectomy 18 (47.4) 39 (65)
Gastrectomy 9 (23.7) 5 (8.3)
Adhesiolysis 4 (10.5) 4 (6.7) .053
Cholecystectomy 5 (13.2) 3 (5)
Other 2 (5.3) 9 (15)
Operative time (min), mean ± SD 126 ± 38 123 ± 45 .672
Relaparotomy, n (%) 4 (10.5) 8 (13.3) .761
Conversion to GA, n (%) 0 (0) 0 (0) n.a.
Local anesthetics
Type, n (%) levo-bupivacaine 7 (18.4) 37 (61.7) <.001
Hyperbaric bupivacaine 35 (92.1) 25 (41.7) <.001
Number (> 1), n (%) 4 (10.5) 2 (3.3) .203
Cumulative dose, median (range) 9.5 (4–25) 7.5 (5–15) .034
Hemodynamic
MAP, mean ± SD 75.4 ± 7.1 72.8 ± 8.5 .120
HR, median (range) 70 (55–92.5) 75 (57.5–115) .013
SpO2, median (range) 98 (92–100) 97 (91.5–100) .543
Diuresis (mL/kg/h), mean ± SD 0.96 ± 0.3 0.9 ± 0.3 .373
Fluid infusion (mL/kg/h), median (range) 15.6 (6.6–33) 18.6 (9–63.6) .059
Vasopressor support
NE use, n (%) 27 (71.1) 50 (83.3) .243
Max dose,§ median (range) 0.09 (0.02–0.3) 0.13 (0.04–0.59) .048
Pain with VAS > 4, n (%) 0 0 n.a.
Intravenous sedation, n (%) 17 (44.7) 57 (95) <.001
PRBCs, n (%) 6 (15.8) 14 (23.3) .519

Complicated acute diverticulitis and ischemic colitis, ovarian neoplasm with abdominal compartmental syndrome, postincisional hernia, colostomy, perforated duodenal diverticulum, and enterocutaneous fistula.

With or without intestinal resection.

Hysterectomy with ovariosalpingectomy, laparoscopic repair of postincisional hernia, stoma reversal, internal bypass, and suture of duodenum.

§

Expressed in μg/kg/min.